BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood. 2003;101:3008-3013. [PMID: 12506014 DOI: 10.1182/blood-2002-08-2527] [Cited by in Crossref: 120] [Cited by in F6Publishing: 108] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Ninivaggi M, Kelchtermans H, Kuijpers MJ, Hemmeryckx B, Heemskerk JWM, Lindhout T, Hoylaerts MF, de Laat B. Whole blood thrombin generation in Bmal1-deficient mice. Thromb Haemost 2017;112:271-5. [DOI: 10.1160/th13-11-0910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gauer JS, Riva N, Page EM, Philippou H, Makris M, Gatt A, Ariëns RAS. Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors. Res Pract Thromb Haemost 2020;4:1269-81. [PMID: 33313466 DOI: 10.1002/rth2.12443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Memtsas VP, Arachchillage DRJ, Gorog DA. Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis. Int J Mol Sci 2021;22:1472. [PMID: 33540604 DOI: 10.3390/ijms22031472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Aleman MM, Walton BL, Byrnes JR, Wolberg AS. Fibrinogen and red blood cells in venous thrombosis. Thromb Res 2014;133 Suppl 1:S38-40. [PMID: 24759140 DOI: 10.1016/j.thromres.2014.03.017] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 11.6] [Reference Citation Analysis]
5 Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007;21:131-42. [PMID: 17208341 DOI: 10.1016/j.blre.2006.11.001] [Cited by in Crossref: 430] [Cited by in F6Publishing: 353] [Article Influence: 30.7] [Reference Citation Analysis]
6 Wolberg AS, Campbell RA. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci 2008;38:15-23. [PMID: 18282807 DOI: 10.1016/j.transci.2007.12.005] [Cited by in Crossref: 162] [Cited by in F6Publishing: 137] [Article Influence: 12.5] [Reference Citation Analysis]
7 Bridge KI, Philippou H, Ariëns R. Clot properties and cardiovascular disease. Thromb Haemost 2014;112:901-8. [PMID: 24899357 DOI: 10.1160/TH14-02-0184] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
8 Bucay I, O'Brien ET 3rd, Wulfe SD, Superfine R, Wolberg AS, Falvo MR, Hudson NE. Physical determinants of fibrinolysis in single fibrin fibers. PLoS One 2015;10:e0116350. [PMID: 25714359 DOI: 10.1371/journal.pone.0116350] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
9 Natorska J, Undas A. Blood coagulation and fibrinolysis in aortic valve stenosis: links with inflammation and calcification. Thromb Haemost 2015;114:217-27. [PMID: 25809537 DOI: 10.1160/TH14-10-0861] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
10 Guzzetta NA, Williams GD, Ramamoorthy C. Current use of factor concentrates in pediatric cardiac anesthesia. Paediatr Anaesth 2017;27:678-87. [DOI: 10.1111/pan.13158] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
11 Gebhart J, Laczkovics C, Posch F, Ay C, Reitter-pfoertner SE, Haslacher H, Muszbek L, Wolberg AS, Pabinger I. Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause. Ann Hematol 2015;94:1301-10. [DOI: 10.1007/s00277-015-2399-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
12 Byrnes JR, Wolberg AS. New findings on venous thrombogenesis. Hamostaseologie 2017;37:25-35. [PMID: 27878206 DOI: 10.5482/HAMO-16-09-0034] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
13 Castellino FJ, Liang Z, Davis PK, Balsara RD, Musunuru H, Donahue DL, Smith DL, Sandoval-Cooper MJ, Ploplis VA, Walsh M. Abnormal whole blood thrombi in humans with inherited platelet receptor defects. PLoS One 2012;7:e52878. [PMID: 23300803 DOI: 10.1371/journal.pone.0052878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
14 Landskroner K, Olson N, Jesmok G. Cross-Species Pharmacologic Evaluation of Plasmin as a Direct-Acting Thrombolytic Agent: Ex Vivo Evaluation for Large Animal Model Development. Journal of Vascular and Interventional Radiology 2005;16:369-77. [DOI: 10.1097/01.rvi.0000148828.40438.d3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Castoldi E, Simioni P, Tormene D, Thomassen MC, Spiezia L, Gavasso S, Rosing J. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J Thromb Haemost 2007;5:971-9. [PMID: 17461930 DOI: 10.1111/j.1538-7836.2007.02448.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
16 Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol. 2017;16:34. [PMID: 28279217 DOI: 10.1186/s12933-017-0515-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 13.5] [Reference Citation Analysis]
17 Kukla M, Waluga M, Żorniak M, Berdowska A, Wosiewicz P, Sawczyn T, Bułdak RJ, Ochman M, Ziora K, Krzemiński T, Hartleb M. Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis. World J Gastroenterol 2017;23:2613-24. [PMID: 28465646 DOI: 10.3748/wjg.v23.i14.2613] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
18 Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. Journal of Biotechnology 2006;124:747-57. [DOI: 10.1016/j.jbiotec.2006.03.042] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
19 Rahmany MB, Hantgan RR, Van Dyke M. A mechanistic investigation of the effect of keratin-based hemostatic agents on coagulation. Biomaterials 2013;34:2492-500. [DOI: 10.1016/j.biomaterials.2012.12.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
20 Cilia La Corte AL, Philippou H, Ariëns RA. Role of fibrin structure in thrombosis and vascular disease. Adv Protein Chem Struct Biol 2011;83:75-127. [PMID: 21570666 DOI: 10.1016/B978-0-12-381262-9.00003-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 18] [Article Influence: 5.4] [Reference Citation Analysis]
21 Chowdary P, Tang A, Watson D, Besser M, Collins P, Creagh MD, Qureshi H, Rokicka M, Nokes T, Diprose P, Gill R. Retrospective Review of a Prothrombin Complex Concentrate (Beriplex P/N) for the Management of Perioperative Bleeding Unrelated to Oral Anticoagulation. Clin Appl Thromb Hemost 2018;24:1159-69. [PMID: 29415562 DOI: 10.1177/1076029617753537] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
22 Chin C. Recombinant activated factor VII. Pediatric Anesthesia 2006;16:907-9. [DOI: 10.1111/j.1460-9592.2006.02034.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Undas A. Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence. Biomed Res Int 2017;2017:8196256. [PMID: 28740853 DOI: 10.1155/2017/8196256] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
24 Sylman JL, Daalkhaijav U, Zhang Y, Gray EM, Farhang PA, Chu TT, Zilberman-Rudenko J, Puy C, Tucker EI, Smith SA, Morrissey JH, Walker TW, Nan XL, Gruber A, McCarty OJT. Differential Roles for the Coagulation Factors XI and XII in Regulating the Physical Biology of Fibrin. Ann Biomed Eng 2017;45:1328-40. [PMID: 27933406 DOI: 10.1007/s10439-016-1771-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
25 Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood 2003;102:535-40. [PMID: 12663453 DOI: 10.1182/blood-2002-10-3150] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
26 Nabiullina RM, Mustafin IG, Zuev YF, Faizullin DA, Litvinov RI, Zubairova LD. Effect of blood microparticles on the kinetics of polymerization and enzymatic hydrolysis of fibrin. Dokl Biochem Biophys 2015;462:151-4. [PMID: 26163207 DOI: 10.1134/S1607672915030035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Hvas A, Sørensen HT, Norengaard L, Christiansen K, Ingerslev J, Sørensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. Journal of Thrombosis and Haemostasis 2007;5:2408-14. [DOI: 10.1111/j.1538-7836.2007.02755.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 5.4] [Reference Citation Analysis]
28 Mittal S, Watson HG. A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions. Br J Haematol 2006;133:355-63. [DOI: 10.1111/j.1365-2141.2006.06023.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
29 Nossent AY, Eikenboom JC, Bertina RM. Plasma coagulation factor levels in venous thrombosis. Semin Hematol 2007;44:77-84. [PMID: 17433899 DOI: 10.1053/j.seminhematol.2007.01.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kremers RM, Mohamed AB, Pelkmans L, Hindawi S, Hemker HC, de Laat HB, Huskens D, Al Dieri R. Thrombin Generating Capacity and Phenotypic Association in ABO Blood Groups. PLoS One 2015;10:e0141491. [PMID: 26509437 DOI: 10.1371/journal.pone.0141491] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
31 Bouma BN, Meijers JC. New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R). Seminars in Hematology 2004;41:13-9. [DOI: 10.1053/j.seminhematol.2003.11.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
32 Campbell RA, Overmyer KA, Bagnell CR, Wolberg AS. Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface. Arterioscler Thromb Vasc Biol 2008;28:2247-54. [PMID: 18974382 DOI: 10.1161/ATVBAHA.108.176008] [Cited by in Crossref: 57] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
33 Hansson KM, Johansson KJ, Wingren C, Fries D, Nelander K, Lövgren A. Recombinant human prothrombin reduced blood loss in a porcine model of dilutional coagulopathy with uncontrolled bleeding. Blood Coagul Fibrinolysis 2017;28:244-53. [PMID: 27428015 DOI: 10.1097/MBC.0000000000000590] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Campbell RA, Fischer TH, Wolberg AS. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation. Br J Haematol 2007;138:82-93. [PMID: 17555451 DOI: 10.1111/j.1365-2141.2007.06617.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
35 Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004;103:2157-61. [PMID: 14630828 DOI: 10.1182/blood-2003-06-2169] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
36 Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858-3864. [PMID: 15328151 DOI: 10.1182/blood-2004-06-2223] [Cited by in Crossref: 181] [Cited by in F6Publishing: 133] [Article Influence: 10.6] [Reference Citation Analysis]
37 Castillo O, Rojas H, Domínguez Z, Anglés-Cano E, Marchi R. Endothelial fibrinolytic response onto an evolving matrix of fibrin. BMC Hematol 2016;16:9. [PMID: 27081493 DOI: 10.1186/s12878-016-0048-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
38 Gaule TG, Ajjan RA. Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges. Int J Mol Sci 2021;22:6916. [PMID: 34203139 DOI: 10.3390/ijms22136916] [Reference Citation Analysis]
39 Mazoyer E, Ripoll L, Gueguen R, Tiret L, Collet J, Bal dit Sollier C, Roussi J, Drouet L. Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution. Blood Coagulation & Fibrinolysis 2009;20:503-10. [DOI: 10.1097/mbc.0b013e32832f5d7a] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
40 Aljamali MN, Kjalke M, Hedner U, Ezban M, Tranholm M. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions. Haemophilia 2009;15:1318-26. [PMID: 19659796 DOI: 10.1111/j.1365-2516.2009.02073.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
41 Ariëns RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013;11 Suppl 1:294-305. [PMID: 23809133 DOI: 10.1111/jth.12229] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 14.3] [Reference Citation Analysis]
42 Zong Y, Antovic A, Soutari NMH, Antovic J, Pruner I. Synergistic Effect of Bypassing Agents and Sequence Identical Analogue of Emicizumab and Fibrin Clot Structure in the In Vitro Model of Hemophilia A. TH Open 2020;4:e94-e103. [PMID: 32704613 DOI: 10.1055/s-0040-1710032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Janion-sadowska A, Natorska J, Siudut J, Zabczyk M, Stanisz A, Undas A. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban. Thromb Haemost 2017;117:1739-49. [DOI: 10.1160/th17-01-0060] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
44 Swanepoel AC, Visagie A, de Lange Z, Emmerson O, Nielsen VG, Pretorius E. The clinical relevance of altered fibrinogen packaging in the presence of 17β-estradiol and progesterone. Thromb Res 2016;146:23-34. [PMID: 27566845 DOI: 10.1016/j.thromres.2016.08.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
45 Sauls DL, Banini AE, Boyd LC, Hoffman M. Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. Journal of Thrombosis and Haemostasis 2007;5:638-9. [DOI: 10.1111/j.1538-7836.2007.02366.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
46 Anderson JA, Weitz JI. Hypercoagulable states. Crit Care Clin 2011;27:933-52, vii. [PMID: 22082521 DOI: 10.1016/j.ccc.2011.09.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
47 Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006;26:1397-404. [PMID: 16574890 DOI: 10.1161/01.ATV.0000219688.43572.75] [Cited by in Crossref: 76] [Cited by in F6Publishing: 19] [Article Influence: 5.1] [Reference Citation Analysis]
48 Chandrashekar A, Singh G, Jonah Garry, Sikalas N, Labropoulos N. Mechanical and Biochemical Role of Fibrin Within a Venous Thrombus. European Journal of Vascular and Endovascular Surgery 2018;55:417-24. [DOI: 10.1016/j.ejvs.2017.12.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
49 Mitrophanov AY, Wolberg AS, Reifman J. Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies. Mol Biosyst 2014;10:2347-57. [PMID: 24958246 DOI: 10.1039/c4mb00263f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
50 Standeven KF, Ariëns RA, Grant PJ. The molecular physiology and pathology of fibrin structure/function. Blood Rev 2005;19:275-88. [PMID: 15963835 DOI: 10.1016/j.blre.2005.01.003] [Cited by in Crossref: 97] [Cited by in F6Publishing: 71] [Article Influence: 6.1] [Reference Citation Analysis]
51 Byrnes JR, Duval C, Wang Y, Hansen CE, Ahn B, Mooberry MJ, Clark MA, Johnsen JM, Lord ST, Lam WA, Meijers JC, Ni H, Ariëns RA, Wolberg AS. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. Blood 2015;126:1940-8. [PMID: 26324704 DOI: 10.1182/blood-2015-06-652263] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 13.0] [Reference Citation Analysis]
52 Asselta R, Paraboschi EM, Duga S. Hereditary Hypofibrinogenemia with Hepatic Storage. Int J Mol Sci 2020;21:E7830. [PMID: 33105716 DOI: 10.3390/ijms21217830] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Whyte CS, Chernysh IN, Domingues MM, Connell S, Weisel JW, Ariens RA, Mutch NJ. Polyphosphate delays fibrin polymerisation and alters the mechanical properties of the fibrin network. Thromb Haemost 2016;116:897-903. [PMID: 27610454 DOI: 10.1160/TH16-01-0062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
54 Polak MW, Siudut J, Plens K, Undas A. Prothrombotic clot properties can predict venous ulcers in patients following deep vein thrombosis: a cohort study. J Thromb Thrombolysis 2019;48:603-9. [PMID: 31432450 DOI: 10.1007/s11239-019-01914-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Kotzé RC, Ariëns RA, de Lange Z, Pieters M. CVD risk factors are related to plasma fibrin clot properties independent of total and or γ' fibrinogen concentration. Thromb Res 2014;134:963-9. [PMID: 25213709 DOI: 10.1016/j.thromres.2014.08.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
56 Augustine TN, van der Spuy WJ, Kaberry LL, Shayi M. Thrombin-Mediated Platelet Activation of Lysed Whole Blood and Platelet-Rich Plasma: A Comparison Between Platelet Activation Markers and Ultrastructural Alterations. Microsc Microanal 2016;22:630-9. [PMID: 27329313 DOI: 10.1017/S1431927616000854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
57 Rusak T, Piszcz J, Misztal T, Brańska-januszewska J, Tomasiak M. Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis. Thrombosis Research 2014;134:192-8. [DOI: 10.1016/j.thromres.2014.04.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
58 Gugerell A, Schossleitner K, Wolbank S, Nürnberger S, Redl H, Gulle H, Goppelt A, Bittner M, Pasteiner W. High thrombin concentrations in fibrin sealants induce apoptosis in human keratinocytes. J Biomed Mater Res A 2012;100:1239-47. [PMID: 22359340 DOI: 10.1002/jbm.a.34007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
59 Kietsiriroje N, Ariëns RAS, Ajjan RA. Fibrinolysis in Acute and Chronic Cardiovascular Disease. Semin Thromb Hemost 2021;47:490-505. [PMID: 33878782 DOI: 10.1055/s-0040-1718923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Fischer TH, Connolly R, Thatte HS, Schwaitzberg SS. Comparison of structural and hemostatic properties of the poly-N-acetyl glucosamine Syvek Patch with products containing chitosan. Microsc Res Tech 2004;63:168-74. [DOI: 10.1002/jemt.20017] [Cited by in Crossref: 50] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
61 Salamanna F, Contartese D, Nicoli Aldini N, Barbanti Brodano G, Griffoni C, Gasbarrini A, Fini M. Bone marrow aspirate clot: A technical complication or a smart approach for musculoskeletal tissue regeneration? J Cell Physiol. 2018;233:2723-2732. [PMID: 28639702 DOI: 10.1002/jcp.26065] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
62 Thatte HS, Zagarins S, Khuri SF, Fischer TH. Mechanisms of Poly-N-Acetyl Glucosamine Polymer–Mediated Hemostasis: Platelet Interactions. Journal of Trauma: Injury, Infection & Critical Care 2004;57:S13-21. [DOI: 10.1097/01.ta.0000136743.12440.89] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
63 Campbell RA, Overmyer KA, Selzman CH, Sheridan BC, Wolberg AS. Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability. Blood 2009;114:4886-96. [PMID: 19797520 DOI: 10.1182/blood-2009-06-228940] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 8.6] [Reference Citation Analysis]
64 Lee JJ, Bruley DF, Kang KA. Effect Of Ph And Imidazole On Protein C Purification From Cohn Fraction Iv-1 By Imac. In: Maguire DJ, Bruley DF, Harrison DK, editors. Oxygen Transport to Tissue XXVIII. Boston: Springer US; 2007. pp. 61-6. [DOI: 10.1007/978-0-387-71764-7_9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
65 Montalbano G, Toumpaniari S, Popov A, Duan P, Chen J, Dalgarno K, Scott WE 3rd, Ferreira AM. Synthesis of bioinspired collagen/alginate/fibrin based hydrogels for soft tissue engineering. Mater Sci Eng C Mater Biol Appl 2018;91:236-46. [PMID: 30033251 DOI: 10.1016/j.msec.2018.04.101] [Cited by in Crossref: 48] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
66 Anderson JA, Weitz JI. Hypercoagulable states. Clin Chest Med 2010;31:659-73. [PMID: 21047574 DOI: 10.1016/j.ccm.2010.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
67 Mann KG, Freeman K. TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy. J Thromb Haemost 2015;13 Suppl 1:S63-71. [PMID: 26149052 DOI: 10.1111/jth.12981] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
68 Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. Anesth Analg 2012;114:275-85. [PMID: 22104070 DOI: 10.1213/ANE.0b013e31823a088c] [Cited by in Crossref: 159] [Cited by in F6Publishing: 55] [Article Influence: 15.9] [Reference Citation Analysis]
69 Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007;27:683-9. [PMID: 17204663 DOI: 10.1161/01.ATV.0000257204.82396.2b] [Cited by in Crossref: 59] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
70 Wolberg AS, Roubey RA. Anti-β2-glycoprotein I antibodies do not increase TF activity by de-encryption. Thrombosis Research 2004;114:67-71. [DOI: 10.1016/j.thromres.2004.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
71 McCarthy Z, Xu S, Rahman A, Bragazzi NL, Corrales-Medina VF, Lee J, Seet BT, Neame D, Thommes E, Heffernan J, Chit A, Wu J. Modelling the linkage between influenza infection and cardiovascular events via thrombosis. Sci Rep 2020;10:14264. [PMID: 32868834 DOI: 10.1038/s41598-020-70753-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Wolberg AS. Fibrinogen and factor XIII: newly recognized roles in venous thrombus formation and composition. Curr Opin Hematol 2018;25:358-64. [PMID: 29994896 DOI: 10.1097/MOH.0000000000000445] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
73 Machlus KR, Lin FC, Wolberg AS. Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood 2011;118:3960-8. [PMID: 21828144 DOI: 10.1182/blood-2011-06-362814] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
74 Wosiewicz P, Żorniak M, Hartleb M, Barański K, Hartleb M, Onyszczuk M, Pilch-Kowalczyk J, Kyrcz-Krzemień S. Portal vein thrombosis in cirrhosis is not associated with intestinal barrier disruption or increased platelet aggregability. Clin Res Hepatol Gastroenterol 2016;40:722-9. [PMID: 27160816 DOI: 10.1016/j.clinre.2016.03.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
75 Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophysical Chemistry 2004;112:223-8. [DOI: 10.1016/j.bpc.2004.07.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
76 Allen GA, Hoffman M, Roberts HR, Monroe DM. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haematol 2006;134:314-9. [DOI: 10.1111/j.1365-2141.2006.06178.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
77 Phang M, Scorgie FE, Seldon M, Garg ML, Lincz LF. Reduction of prothrombin and Factor V levels following supplementation with omega-3 fatty acids is sex dependent: a randomised controlled study. J Nutr Biochem 2014;25:997-1002. [PMID: 24997005 DOI: 10.1016/j.jnutbio.2014.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
78 White NJ, Martin EJ, Brophy DF, Ward KR. Coagulopathy and traumatic shock: characterizing hemostatic function during the critical period prior to fluid resuscitation. Resuscitation 2010;81:111-6. [PMID: 19854556 DOI: 10.1016/j.resuscitation.2009.09.017] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
79 Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008;112:2810-6. [PMID: 18544683 DOI: 10.1182/blood-2008-03-145755] [Cited by in Crossref: 154] [Cited by in F6Publishing: 128] [Article Influence: 11.8] [Reference Citation Analysis]
80 Bertaggia Calderara D, Aliotta A, Zermatten MG, Kröll D, Stirnimann G, Alberio L. Hyper-coagulability in obese patients accurately identified by combinations of global coagulation assay parameters. Thrombosis Research 2020;187:91-102. [DOI: 10.1016/j.thromres.2020.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
81 Undas A, Ariëns RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011;31:e88-99. [PMID: 21836064 DOI: 10.1161/ATVBAHA.111.230631] [Cited by in Crossref: 301] [Cited by in F6Publishing: 115] [Article Influence: 30.1] [Reference Citation Analysis]
82 Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004;2:402-13. [DOI: 10.1111/j.1538-7933.2003.00617.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 7.1] [Reference Citation Analysis]
83 Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29:17-24. [PMID: 25294122 DOI: 10.1016/j.blre.2014.09.003] [Cited by in Crossref: 285] [Cited by in F6Publishing: 188] [Article Influence: 40.7] [Reference Citation Analysis]
84 Varin R, Mirshahi S, Mirshahi P, Klein C, Jamshedov J, Chidiac J, Perzborn E, Mirshahi M, Soria C, Soria J. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban. Thromb Res 2013;131:e100-9. [PMID: 23313382 DOI: 10.1016/j.thromres.2012.11.029] [Cited by in Crossref: 52] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
85 Wang H, Morales-Levy M, Rose J, Mackey LC, Bodary P, Eitzman D, Homeister JW. α(1,3)-Fucosyltransferases FUT4 and FUT7 control murine susceptibility to thrombosis. Am J Pathol 2013;182:2082-93. [PMID: 23562273 DOI: 10.1016/j.ajpath.2013.02.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
86 Kim E, Kim OV, Machlus KR, Liu X, Kupaev T, Lioi J, Wolberg AS, Chen DZ, Rosen ED, Xu Z, Alber M. Correlation between fibrin network structure and mechanical properties: an experimental and computational analysis. Soft Matter 2011;7:4983. [DOI: 10.1039/c0sm01528h] [Cited by in Crossref: 36] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
87 Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006;26:41-8. [PMID: 16254201 DOI: 10.1161/01.ATV.0000193624.28251.83] [Cited by in Crossref: 240] [Cited by in F6Publishing: 84] [Article Influence: 15.0] [Reference Citation Analysis]
88 Goswami N, Taucher AA, Brix B, Roessler A, Koestenberger M, Reibnegger G, Cvirn G. Coagulation Changes during Central Hypovolemia across Seasons. J Clin Med 2020;9:E3461. [PMID: 33121195 DOI: 10.3390/jcm9113461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Scott EM, Ariëns RA, Grant PJ. Genetic and Environmental Determinants of Fibrin Structure and Function: Relevance to Clinical Disease. ATVB 2004;24:1558-66. [DOI: 10.1161/01.atv.0000136649.83297.bf] [Cited by in Crossref: 96] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
90 Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005;131:645-55. [PMID: 16351642 DOI: 10.1111/j.1365-2141.2005.05820.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 88] [Article Influence: 6.3] [Reference Citation Analysis]
91 Undas A, Celinska-lowenhoff M, Lowenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006;4:1029-36. [DOI: 10.1111/j.1538-7836.2006.01882.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 5.9] [Reference Citation Analysis]
92 Shoji T, Nakasa T, Yoshizuka M, Yamasaki T, Yasunaga Y, Adachi N, Ochi M. Comparison of fibrin clots derived from peripheral blood and bone marrow. Connect Tissue Res 2017;58:208-14. [PMID: 27462987 DOI: 10.1080/03008207.2016.1215443] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
93 Mcdonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost 2007;5:1577-83. [DOI: 10.1111/j.1538-7836.2007.02647.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
94 Le Gal G, Delahousse B, Lacut K, Malaviolle V, Regina S, Blouch M, Couturaud F, Mottier D, Oger E, Gruel Y. Fibrinogen Aα-Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolism. Thrombosis Research 2007;121:333-8. [DOI: 10.1016/j.thromres.2007.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
95 Nowak-Göttl U, Weiler H, Hernandez I, Thedieck S, Seehafer T, Schulte T, Stoll M. Fibrinogen alpha and gamma genes and factor VLeiden in children with thromboembolism: results from 2 family-based association studies. Blood 2009;114:1947-53. [PMID: 19515723 DOI: 10.1182/blood-2009-04-218727] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
96 Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 2011;117:4953-63. [PMID: 21355090 DOI: 10.1182/blood-2010-11-316885] [Cited by in Crossref: 106] [Cited by in F6Publishing: 90] [Article Influence: 10.6] [Reference Citation Analysis]
97 Aleman MM, Walton BL, Byrnes JR, Wang JG, Heisler MJ, Machlus KR, Cooley BC, Wolberg AS. Elevated prothrombin promotes venous, but not arterial, thrombosis in mice. Arterioscler Thromb Vasc Biol 2013;33:1829-36. [PMID: 23723374 DOI: 10.1161/ATVBAHA.113.301607] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
98 Ariëns RA. Novel mechanisms that regulate clot structure/function. Thromb Res 2016;141 Suppl 2:S25-7. [PMID: 27207417 DOI: 10.1016/S0049-3848(16)30358-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
99 Domingues MM, Macrae FL, Duval C, McPherson HR, Bridge KI, Ajjan RA, Ridger VC, Connell SD, Philippou H, Ariëns RA. Thrombin and fibrinogen γ' impact clot structure by marked effects on intrafibrillar structure and protofibril packing. Blood 2016;127:487-95. [PMID: 26608329 DOI: 10.1182/blood-2015-06-652214] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
100 Marchi R, Marcos L, Paradisi I. Comparison by sex between thrombin generation and fibrin network characteristics in a healthy population. Clinica Chimica Acta 2015;441:86-9. [DOI: 10.1016/j.cca.2014.12.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
101 Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and Fibrin in Hemostasis and Thrombosis. Arterioscler Thromb Vasc Biol 2017;37:e13-21. [PMID: 28228446 DOI: 10.1161/ATVBAHA.117.308564] [Cited by in Crossref: 111] [Cited by in F6Publishing: 44] [Article Influence: 55.5] [Reference Citation Analysis]
102 Larsen JB, Hvas AM. Fibrinolytic Alterations in Sepsis: Biomarkers and Future Treatment Targets. Semin Thromb Hemost 2021;47:589-600. [PMID: 33878784 DOI: 10.1055/s-0041-1725096] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Kanji R, Gue YX, Memtsas V, Gorog DA. Fibrinolysis in Platelet Thrombi. Int J Mol Sci 2021;22:5135. [PMID: 34066261 DOI: 10.3390/ijms22105135] [Reference Citation Analysis]
104 Pruner I, Farm M, Tomic B, Gvozdenov M, Kovac M, Miljic P, Soutari NMH, Antovic A, Radojkovic D, Antovic J, Djordjevic V. The Silence Speaks, but We Do Not Listen: Synonymous c.1824C>T Gene Variant in the Last Exon of the Prothrombin Gene as a New Prothrombotic Risk Factor. Clin Chem 2020;66:379-89. [PMID: 32040579 DOI: 10.1093/clinchem/hvz015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI)—How does thrombin regulate fibrinolysis? Annals of Medicine 2009;38:378-88. [DOI: 10.1080/07853890600852898] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
106 Wolberg AS. Plasma and cellular contributions to fibrin network formation, structure and stability. Haemophilia 2010;16 Suppl 3:7-12. [PMID: 20586795 DOI: 10.1111/j.1365-2516.2010.02253.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
107 Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol 2011;31:494-9. [PMID: 21325671 DOI: 10.1161/ATVBAHA.110.213389] [Cited by in Crossref: 88] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
108 Scipione CA, Mcainey JT, Simard DJ, Bazzi ZA, Gemin M, Romagnuolo R, Macrae FL, Ariëns RA, Hegele RA, Auld J, Gauld JW, Boffa MB, Koschinsky ML. Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a). J Thromb Haemost 2017;15:1834-44. [DOI: 10.1111/jth.13759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]